Abstract
Regulator of G-protein signaling 9-2 (RGS9-2) is a striatal-enriched signal-transduction modulator known to have a critical role in the development of addiction-related behaviors following exposure to psychostimulants or opioids. RGS9-2 controls the function of several G-protein-coupled receptors, including dopamine receptor and mu opioid receptor (MOR). We previously showed that RGS9-2 complexes negatively control morphine analgesia, and promote the development of morphine tolerance. In contrast, RGS9-2 positively modulates the actions of other opioid analgesics, such as fentanyl and methadone. Here we investigate the role of RGS9-2 in regulating responses to oxycodone, an MOR agonist prescribed for the treatment of severe pain conditions that has addictive properties. Using mice lacking the Rgs9 gene (RGS9KO), we demonstrate that RGS9-2 positively regulates the rewarding effects of oxycodone in pain-free states, and in a model of neuropathic pain. Furthermore, although RGS9-2 does not affect the analgesic efficacy of oxycodone or the expression of physical withdrawal, it opposes the development of oxycodone tolerance, in both acute pain and chronic neuropathic pain models. Taken together, these data provide new information on the signal-transduction mechanisms that modulate the rewarding and analgesic actions of oxycodone.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Anderson GR, Semenov A, Song JH, Martemyanov KA (2007). The membrane anchor R7BP controls the proteolytic stability of the striatal specific RGS protein, RGS9-2. J Biol Chem 282: 4772–4781.
Bailey CP, Connor M (2005). Opioids: cellular mechanisms of tolerance and physical dependence. Curr Opin Pharmacol 5: 60–68.
Baliki MN, Petre B, Torbey S, Herrmann KM, Huang L, Schnitzer TJ et al (2012). Corticostriatal functional connectivity predicts transition to chronic back pain. Nat Neurosci 15: 1117–1119.
Baliki MN, Apkarian AV (2015). Nociception, pain, negative moods, and behavior selection. Neuron 87: 474–491.
Butler SF, Black RA, Cassidy TA, Dailey TM, Budman SH (2011). Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J 8: 29.
Carise D, Dugosh KL, Mclellan AT, Camilleri A, Woody GE, Lynch KG (2007). Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry 164: 1750–1756.
Charlton JJ, Allen BP, Psifogeorgou K, Chakravarty S, Gomes I, Neve RL et al (2008). Multiple actions of spinophilin modulate mu opioid receptor function. Neuron 58: 238–247.
Collins D, Reed B, Zhang Y, Kreek MJ (2016). Sex differences in responsiveness to the prescription opioid oxycodone in mice. Pharmacol Biochem Behav 148: 99–105.
Comer SD, Sullivan MA, Whittington RA, Vosburg SK, Kowalczyk WJ (2007). Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology 33: 1179–1191.
Dart RC, Surratt HL, Cicero TJ, Parrino MW, Severtson SG, Bucher-Bartelson B et al (2015). Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med 372: 1573–1574.
Eidson LN, Murphy AZ (2013). Blockade of Toll-like receptor 4 attenuates morphine tolerance and facilitates the pain relieving properties of morphine. J Neurosci 33: 15952–15963.
Emery MA, Bates MS, Wellman PJ, Eitan S (2015). Differential effects of oxycodone, hydrocodone, and morphine on the responses of D2/D3 dopamine receptors. Behav Brain Res 284: 37–41.
Ewan EE, Martin TJ (2011). Opioid facilitation of rewarding electrical brain stimulation is suppressed in rats with neuropathicpain. Anesthesiology 14: 624–632.
Garzón J, RodrÃguez-Muñoz M, Sánchez-Blázquez P (2005). Morphine alters the selective association between mu-opioid receptors and specific RGS proteins in mouse periaqueductal gray matter. Neuropharmacology 48: 853–868.
Gaspari S, Papachatzaki MM, Koo JW, Carr FB, Tsimpanouli ME, Stergiou E et al (2014). Nucleus accumbens-specific interventions in RGS9-2 activity modulate responses to morphine. Neuropsychopharmacology 39: 1968–1977.
Gold SJ, Han MH, Herman AE, Ni YG, Pudiak CM, Aghajanian GK et al (2003). Regulation of RGS proteins by chronic morphine in rat locus coeruleus. Eur J Neurosci 17: 971–980.
Gruccu G (2007). Treatment of painful neuropathy. Curr Opin Neurol 20: 531–535.
Han MH, Renthal W, Ring RH, Rahman Z, Psifogeorgou K, Howland D et al (2010). Brain region specific actions of regulator of G protein signaling 4 oppose morphine reward and dependence but promote analgesia. Biol Psychiatry 67: 761–769.
Hermanns K, Junker U, Nolte T (2012). Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain—results from a large observational study. Expert Opin Pharmacother 13: 299–311.
Hipolito L, Wilson-Poe A, Campos-Jurado Y, Zhong E, Gonzalez-Romero J, Virag L et al (2015). Inflammatory pain promotes increased opioid self-administration: role of dysregulated ventral tegmental area opioid receptors. J Neurosci 35: 12217–12231.
Hollinger S, Hepler J (2002). Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacol Rev 54: 527–559.
Jayaraman M, Zhou H, Jia L, Cain MD, Blumer KJ (2009). R9AP and R7BP: traffic cops for the RGS7 family in phototransduction and neuronal GPCR signaling. Trends Pharmacol Sci 30: 17–24.
Kimple AJ, Bosch DE, Giguere PM, Siderovski DP (2011). Regulators of G-protein signaling and their substrates: promises and challenges in their use as drug discovery targets. Pharmacol Rev 63: 728–749.
Koch T, Widera A, Bartzsch K, Schulz S, Brandenburg LO, Wundrack N et al (2005). Receptor endocytosis counteracts the development of opioid tolerance. Mol Pharmacol 67: 280–287.
Kovoor A, Seyffarth P, Ebert J, Barghshoon S, Chen CK, Schwarz S et al (2005). D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways. J Neurosci 25: 2157–2165.
Ling W, Mooney L, Hillhouse M (2011). Prescription opioid abuse, pain and addiction: clinical issues and implications. Drug Alcohol Rev 30: 300–305.
Mehalick ML, Ingram SL, Aicher SA, Morgan MM (2013). Chronic Inflammatory pain prevents tolerance to the antinociceptive effect of morphine microinjected into the ventrolateral periaqueductal gray of the rat. J Pain 12: 1601–1610.
Mitsi V, Terzi D, Purushothaman I, Manouras L, Gaspari S, Neve RL et al (2015). RGS9-2—controlled adaptations in the striatum determine the onset of action and efficacy of antidepressants in neuropathic pain states. Proc Natl Acad Sci USA 112: E5088–E5097.
Mitsi V, Zachariou V (2016). Modulation of pain, nociception, and analgesia by the brain reward center. Neuroscience 338: 81–92.
Muller DL, Unterwald EM (2004). In vivo regulation of extracellular signal-regulated protein kinase (ERK) and protein kinase B (Akt) phosphorylation by acute and chronic morphine. J Pharmacol Exp Ther 310: 774–782.
Navratilova E, Xie JY, Okun A, Qu C, Eyde N, Ci S et al (2012). Pain relief produces negative reinforcement through activation of mesolimbic reward-valuation circuitry. Proc Natl Acad Sci USA 109: 20709–20713.
Navratilova E, Porreca F (2014). Reward and motivation in pain and pain relief. Nat Neurosci 17: 1304–1312.
Niikura K, Zhang Y, Ho A, Kreek M (2013). Oxycodone-induced conditioned place preference and sensitization of locomotor activity in adolescent and adult mice. Pharmacol Biochem Behav 110: 112–116.
Ozaki S, Narita M, Narita M, Iino M, Sugita J, Matsumura Y et al (2002). Suppression of the morphine-induced rewarding effect in the rat with neuropathic pain: implication of the reduction in mu-opioid receptor functions in the ventral tegmental area. J Neurochem 82: 1192–1198.
Ozaki S, Narita M, Narita M, Iino M, Miyoshi K, Suzuki T (2003). Suppression of the morphine-induced rewarding effect and G-protein activation in the lower midbrain following nerve injury in the mouse: involvement of G-protein-coupled receptor kinase 2. Neuroscience 116: 89–97.
Pradhan A, Siau C, Constantin A, Clarke P (2006). Chronic morphine administration results in tolerance to delta opioid receptor-mediated antinociception. Neuroscience 141: 947–954.
Psifogeorgou K, Papakosta P, Russo SJ, Neve RL, Kardassis D, Gold SJ et al (2007). RGS9-2 is a negative modulator of μ-opioid receptor function. J Neurochem 103: 617–625.
Psifogeorgou K, Terzi D, Papachatzaki MM, Varidaki A, Ferguson D, Gold SJ et al (2011). A unique role of RGS9-2 in the striatum as a positive or negative regulator of opiate analgesia. J Neurosci 31: 5617–5624.
Quillinan N, Lau EK, Virk M, Zastrow MV, Williams JT (2011). Recovery from μ-opioid receptor desensitization after chronic treatment with morphine and methadone. J Neurosci 31: 4434–4443.
Raehal KM, Bohn LM (2005). Mu opioid receptor regulation and opiate responsiveness. AAPS J 7: E587–E591.
Rahman Z, Schwarz J, Gold SJ, Zachariou V, Wein MN, Choi K-H et al (2003). RGS9 modulates dopamine signaling in the basal ganglia. Neuron 38: 941–952.
Ray WA, Chung CP, Murray KT, Hall K, Stein CM (2016). Prescription of long-acting opioids and mortality in patients with chronic noncancer pain. JAMA 315: 2415–2423.
Sanchez V, Carpenter MD, Yohn NL, Blendy JA (2016). Long-lasting effects of adolescent oxycodone exposure on reward-related behavior and gene expression in mice. Psychopharmacology 233: 3991–4002.
Schwartz N, Temkin P, Jurado S, Lim BK, Heifets BD, Polepalli JS et al (2014). Decreased motivation during chronic pain requires long-term depression in the nucleus accumbens. Science 345: 535–542.
Shields SD, Eckert WA, Basbaum AI (2003). Spared nerve injury model of neuropathic pain in the mouse: a behavioral and anatomic analysis. J Pain 4: 465–470.
Spiller H, Lorenz DJ, Bailey EJ, Dart RC (2009). Epidemiological trends in abuse and misuse of prescription opioids. J Addict Dis 28: 130–136.
Stratinaki M, Varidaki A, Mitsi V, Ghose S, Magida J, Dias C et al (2013). Regulator of G protein signaling 4 is a crucial modulator of antidepressant drug action in depression and neuropathic pain models. Proc Natl Acad Sci USA 110: 8254–8259.
Taylor AMW, Castonguay A, Taylor AJ, Murphy NP, Ghogha A, Cook C et al (2015). Microglia disrupt mesolimbic reward circuitry in chronic pain. J Neurosci 35: 8442–8450.
Terzi D, Stergiou E, King SL, Zachariou V (2009). Regulators of G protein signaling in neuropsychiatric disorders. Prog Mol Biol Transl Sci 86: 299–333.
Terzi D, Cao Y, Agrimaki I, Martemyanov KA, Zachariou V (2011). R7BP modulates opiate analgesia and tolerance but not withdrawal. Neuropsychopharmacology 37: 1005–1012.
Terzi D, Gaspari S, Manouras L, Descalzi G, Mitsi V, Zachariou V (2014). RGS9-2 modulates sensory and mood related symptoms of neuropathic pain. Neurobiol Learn Mem 115: 43–48.
Traynor JR, Terzi D, Caldarone BJ, Zachariou V (2009). RGS9-2: probing an intracellular modulator of behavior as a drug target. Trends Pharmacol Sci 30: 105–111.
Walwyn WM, Miotto KA, Evans CJ (2010). Opioid pharmaceuticals and addiction: The issues, and research directions seeking solutions. Drug Alcohol Depend 108: 156–165.
Wu Y, Na X, Zang Y, Cui Y, Xin W, Pang R et al (2014). Upregulation of tumor necrosis factor-alpha in nucleus accumbens attenuates morphine-induced rewarding in a neuropathic pain model. Biochem Biophys Res Commun 449: 502–507.
Yalcin I, Barthas F, Barrot M (2014). Emotional consequences of neuropathic pain: Insight from preclinical studies. Neurosci Biobehav Rev 47: 154–164.
Zachariou V, Georgescu D, Sanchez N, Rahman Z, Dileone R, Berton O et al (2003). Essential role for RGS9 in opiate action. Proc Natl Acad Sci USA 100: 13656–13661.
Zhang Y, Mayer-Blackwell B, Schlussman SD, Randesi M, Butelman ER, Ho A et al (2013). Extended access oxycodone self-administration and neurotransmitter receptor gene expression in the dorsal striatum of adult C57BL/6J mice. Psychopharmacology 231: 1277–1287.
Zhang Y, Brownstein A, Buonora M, Niikura K, Ho A, Rosa JCD et al (2015). Self administration of oxycodone alters synaptic plasticity gene expression in the hippocampus differentially in male adolescent and adult mice. Neuroscience 285: 34–46.
Zhang Y, Windisch K, Altschuler J, Rahm S, Butelman ER, Kreek MJ (2016). Adolescent oxycodone self administration alters subsequent oxycodone-induced conditioned place preference and anti-nociceptive effect in C57BL/6J mice in adulthood. Neuropharmacology 111: 314–322.
Zhu Y, Zhang H (2015). Evidence for the contribution of genetic variations in regulator of G protein signaling 9 to the genetic susceptibility of heroin dependence. Mol Med Rep 11: 3908–3913.
Acknowledgements
This work was supported by the Greek Secretariat of Research and Technology-Greek Ministry of Education and Religious Sffairs, the 7th EU Framework (Aristia I) and by NINDS (NS086444).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gaspari, S., Cogliani, V., Manouras, L. et al. RGS9-2 Modulates Responses to Oxycodone in Pain-Free and Chronic Pain States. Neuropsychopharmacol 42, 1548–1556 (2017). https://doi.org/10.1038/npp.2017.4
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/npp.2017.4
This article is cited by
-
Genetic mouse models in opioid research: current status and future directions
Journal of Neural Transmission (2024)
-
Tianeptine promotes lasting antiallodynic effects in a mouse model of neuropathic pain
Neuropsychopharmacology (2023)
-
Single nucleus transcriptomic analysis of rat nucleus accumbens reveals cell type-specific patterns of gene expression associated with volitional morphine intake
Translational Psychiatry (2022)
